Publications by authors named "Patrick S Parfrey"

Article Synopsis
  • The PROTECT trials studied how safe a new kidney disease treatment called vadadustat is compared to another treatment called darbepoetin alfa in patients who don't need dialysis.
  • The results showed no difference in major heart-related problems among patients in the U.S., but those treated with vadadustat outside the U.S. had more issues, especially in Brazil and South Africa.
  • The study included over 1,700 patients who had never been treated before, and they looked at different factors like kidney function and deaths related to kidney failure in those regions.
View Article and Find Full Text PDF
Article Synopsis
  • In the PROTECT trials, a new drug called vadadustat was compared to a drug named darbepoetin alfa for treating patients with kidney disease and anemia.
  • They found that while vadadustat worked similarly for improving blood health, it had more risks for serious heart problems in certain regions, especially in Europe.
  • Overall, patients in Europe experienced a higher rate of heart problems compared to those in the US and other regions, suggesting location may affect treatment outcomes.
View Article and Find Full Text PDF

Objective: Leptin (LEP) is an obesity-associated adipokine associated with tumor cell growth. We examined the relevance of genetic variants of and leptin receptor () to colorectal cancer (CRC) survival by using data from the Newfoundland Familial Colorectal Cancer Study.

Methods: A total of 532 patients newly diagnosed with CRC between 1997 and 2003 were followed up until April 2010.

View Article and Find Full Text PDF
Article Synopsis
  • Vadadustat is being studied as an oral alternative to injectable treatments for anemia in patients on peritoneal dialysis, showing comparable safety and efficacy to darbepoetin alfa in clinical trials.
  • A post hoc analysis of the INNO2VATE trials indicated that for patients on peritoneal dialysis, the rates of major cardiovascular events and changes in hemoglobin levels were similar for both treatments.
  • Adverse events were reported less frequently in the vadadustat group compared to the darbepoetin alfa group, suggesting a potentially safer profile for vadadustat in this population.
View Article and Find Full Text PDF
Article Synopsis
  • - Anemia is common in chronic kidney disease (CKD) and affects patients' quality of life, but current treatments like erythropoiesis-stimulating agents require ongoing injections, which can be inconvenient and have safety concerns related to cardiovascular risks.
  • - The study analyzed the safety of vadadustat, a new oral treatment for CKD-related anemia, by pooling data from four clinical trials involving over 7,300 patients.
  • - Results showed that vadadustat had comparable rates of treatment-emergent adverse events, serious adverse events, and fatal events to darbepoetin alfa, the standard injectable treatment, indicating it may be a safe alternative for managing anemia in CKD patients.
View Article and Find Full Text PDF

Background: Paradoxically epidemiological data illustrate a negative relationship between dietary folate intake and colorectal cancer (CRC) risk. The occurrence and progression of CRC may be influenced by variants in some key enzyme coding genes in the folate metabolic pathway. We investigated the correlation between genetic variants in methionine synthase reductase () and methylenetetrahydrofolate reductase () and CRC survival.

View Article and Find Full Text PDF

We examined dietary fiber intake for its relevance to Colorectal cancer (CRC) survival in a cohort of CRC patients and a meta-analysis including results from four prospective cohort studies. We analyzed 504 CRC patients enrolled in the Newfoundland Familial Colorectal Cancer Study (NFCCS) who were newly diagnosed with CRC between 1999 and 2003. Follow-up for deaths was through April 2010.

View Article and Find Full Text PDF
Article Synopsis
  • * A clinical trial showed that vadadustat, a new treatment, was as effective as darbepoetin alfa in raising and maintaining hemoglobin levels in CKD patients, while also increasing EPO levels and circulating red blood cells.
  • * Vadadustat improved iron availability for erythroid cells and altered iron markers in the blood, suggesting it may help enhance red blood cell production more effectively than darbepoetin alfa.
View Article and Find Full Text PDF

Background: The incidence of colorectal cancer (CRC) among individuals aged younger than 50 years has been increasing. As screening guidelines lower the recommended age of screening initiation, concerns including the burden on screening capacity and costs have been recognized, suggesting that an individualized approach may be warranted. We developed risk prediction models for early-onset CRC that incorporate an environmental risk score (ERS), including 16 lifestyle and environmental factors, and a polygenic risk score (PRS) of 141 variants.

View Article and Find Full Text PDF

Objective: The use of antipsychotics to treat seniors in long-term care facilities (LTCFs) has raised concern because of health consequences (i.e., increased risk of falls, stroke, death) in this vulnerable population.

View Article and Find Full Text PDF

Background: Incidence of early-onset (younger than 50 years of age) colorectal cancer (CRC) is increasing in many countries. Thus, elucidating the role of traditional CRC risk factors in early-onset CRC is a high priority. We sought to determine whether risk factors associated with late-onset CRC were also linked to early-onset CRC and whether association patterns differed by anatomic subsite.

View Article and Find Full Text PDF
Article Synopsis
  • Vadadustat is a medication that stimulates the production of erythropoietin, helping treat anemia in patients with chronic kidney disease on dialysis.
  • Two large phase 3 trials compared its safety and effectiveness to darbepoetin alfa, focusing on cardiovascular events and hemoglobin levels over time.
  • Results showed similar rates of major adverse cardiovascular events between the two treatments, but vadadustat led to slightly lower increases in hemoglobin levels in both incident and prevalent dialysis-dependent chronic kidney disease patients.
View Article and Find Full Text PDF
Article Synopsis
  • * The study involved two large Phase 3 clinical trials focusing on patients with low hemoglobin levels; the main goal was to assess the safety of vadadustat compared to darbepoetin, specifically looking at major cardiovascular events.
  • * Results showed that vadadustat did not meet the safety benchmark compared to darbepoetin, as indicated by a higher hazard ratio for major adverse cardiovascular events, and there was minimal difference in hemoglobin improvement between the two treatments.
View Article and Find Full Text PDF

Knowledge translation (KT) is critical to realizing real-world impacts from health research by reducing the amount of time it takes for evidence to inform practice. One way this is achieved is by engaging with knowledge users throughout the process to ensure that research responds to their needs. It is also important to share the study results in a way that is useful, accessible, and relevant to knowledge user groups.

View Article and Find Full Text PDF

The quantity of health spending does not equate directly to the quality of healthcare. Social spending and nonmedical determinants of health impact on health outcomes. The value of health spending in the United States is limited by the high cost of goods and labor, and administrative costs, high use of low-level care, and lack of basic healthcare coverage in a substantial minority of the population.

View Article and Find Full Text PDF

The intention-to-treat analysis is the gold standard for evaluating the efficacy in a randomized controlled trial. However, when non-adherence to randomized treatments is high the actual treatment effect may be underestimated. The impact of drop-out from the intervention group or drop-in to the control group may be controlled by trial design, increasing the sample size, effective study execution, and a pre-specified analytical plan to take contamination into account.

View Article and Find Full Text PDF

Quality-of-life (QoL) outcomes are important elements of randomized controlled trials. The instruments for measurement of QoL vary but usually multiple comparisons are possible, a concern that can be offset by prespecifying the outcomes of interest. Missing data may threaten the validity of QoL assessments in trials.

View Article and Find Full Text PDF

When analyzing the results of a trial, the primary outcome variable must be kept in clear focus. In the analysis plan, consideration must be given to comparing the characteristics of the subjects, taking account of differences in these characteristics, intention-to-treat analysis, interim analyses and stopping rules, mortality comparisons, composite outcomes, research design including run-in periods, factorial, stratified and crossover designs, number needed to treat, power issues, multivariate modeling, subgroup analysis, competing risks, and hypothesis-generating analyses.

View Article and Find Full Text PDF

Today's clinical practice relies on the application of well-designed clinical research, the gold standard test of an intervention being the randomized controlled trial. Principles of the randomized control trial include emphasis on the principal research question, randomization, blinding; definitions of outcome measures, of inclusion and exclusion criteria, and of co-morbid and confounding factors; enrolling an adequate sample size; planning data management and analysis; preventing challenges to trial integrity such as drop-out, drop-in, and bias. The application of pre-trial planning is stressed to ensure the proper application of epidemiological principles resulting in clinical studies that are feasible and generalizable.

View Article and Find Full Text PDF

In longitudinal studies, the relationship between exposure and disease can be measured once or multiple times while participants are monitored over time. Traditional regression techniques are used to model outcome data when each epidemiological unit is observed once. These models include generalized linear models for quantitative continuous, discrete, or qualitative outcome responses, and models for time-to-event data.

View Article and Find Full Text PDF

Statistical models are used to study the relationship between exposure and disease while accounting for the potential role of other factors' impact upon outcomes. This adjustment is useful to obtain unbiased estimates of true effects or to predict future outcomes. Statistical models include a systematic and an error component.

View Article and Find Full Text PDF

Clinical epidemiological research entails assessing the burden and etiology of disease, the diagnosis and prognosis of disease, the efficacy of preventive measures or treatments, the analysis of the risks and benefits of diagnostic and therapeutic maneuvers, and the evaluation of health care services. In all areas, the main focus is to describe the relationship between exposure and outcome and to determine one of the following: prevalence, incidence, cause, prognosis, or effect of treatment. The accuracy of these conclusions is determined by the validity of the study.

View Article and Find Full Text PDF

Clinical epidemiology is the science of human disease investigation with a focus on diagnosis, prognosis, and treatment. The generation of a reasonable question requires definition of patients, interventions, controls, and outcomes. The goal of research design is to minimize error, ensure adequate samples, measure input and output variables appropriately, consider external and internal validities, limit bias, and address clinical as well as statistical relevance.

View Article and Find Full Text PDF
Article Synopsis
  • Understanding the diverse causes of colorectal cancer (CRC) is essential for developing tailored prevention and treatment strategies, as tumors in different locations may develop through distinct mechanisms.
  • A genome-wide association study involving over 48,000 CRC cases revealed 13 new specific risk loci linked to CRC, highlighting significant differences in genetic factors between tumors in the proximal (early) and distal (later) regions of the colorectum.
  • The findings indicate that the genetic risk factors for proximal and distal CRC are different, suggesting that prevention and treatment strategies should be tailored based on the tumor's anatomical location.
View Article and Find Full Text PDF
Article Synopsis
  • Current guidelines recommend using erythropoiesis-stimulating agents (ESAs) for managing anemia in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD), with vadadustat being an investigational oral treatment that boosts erythropoietin production.
  • The PROTECT program consists of two Phase 3 clinical trials comparing the safety and efficacy of vadadustat to darbepoetin alfa in adult patients with anemia due to NDD-CKD, focusing on different patient groups based on their prior ESA treatment status.
  • Both trials assess primary outcomes like changes in hemoglobin levels and major cardiovascular events over defined treatment periods, aiming to provide valuable insights into vadadustat's role in
View Article and Find Full Text PDF